NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast CancerBreast Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00001239
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection
Completed
- Conditions
- Candidiasis, OralEating DisordersHIV InfectionsSpeech Disorders
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001448
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection
Phase 1
Completed
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00001443
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
The Impact of Starbright World on Children Being Treated at the NIH
Completed
- Conditions
- Child, Hospitalized
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00001816
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
Completed
- Conditions
- Lymphoma, Non-Hodgkin
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT00001301
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study
Phase 3
Completed
- Conditions
- Osteosarcoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 260
- Registration Number
- NCT00001217
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
Phase 1
Completed
- Conditions
- Neoplasm
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00001341
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00001269
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Voriconazole to Prevent Systemic Fungal Infections in Children
Phase 1
Completed
- Conditions
- AspergillosisCandidiasisFungal DiseasesMycoses
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00005912
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
Phase 3
Completed
- Conditions
- Candidiasis, OralGastrointestinal DiseasesStomatitis
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00001812
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath